Resource Type

Journal Article 5

Year

2023 1

2022 1

2019 1

2016 1

2007 1

Keywords

EGFR 2

ADCP 1

AZD9291 1

EAI045 1

EGFR inhibitor 1

S492R EGFR ectodomain mutation 1

acquired resistance 1

anti-CD47 antibody 1

apoptosis 1

colorectal cancer 1

combination strategy 1

immunnotherapy 1

lung cancer 1

mAb CH12 1

osimertinib 1

tyrosine kinase inhibitor 1

open ︾

Search scope:

排序: Display mode:

Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 701-713 doi: 10.1007/s11684-022-0951-0

Abstract: management of the inevitable acquired resistance to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs), such as osimertinib, which have shown remarkable success inthe treatment of advanced NSCLC with EGFR activating mutations, in order to achieve maximal responsehas been clearly shown that effective induction of apoptosis is a key mechanism for third generation EGFR-TKIsmeans promises an effective strategy for the management of acquired resistance to third generation EGFR-TKIs

Keywords: acquired resistance     EGFR inhibitor     apoptosis     lung cancer    

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors

Shuhang Wang,Yongping Song,Feifei Yan,Delong Liu

Frontiers of Medicine 2016, Volume 10, Issue 4,   Pages 383-388 doi: 10.1007/s11684-016-0488-1

Abstract:

The tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are becoming theAcquired mutations in EGFR account for one of the major mechanisms of resistance toThree generations of EGFR TKIs have been used in clinical applications.The mechanisms of resistance to third-generation inhibitors reported to date include the EGFRas the latest development of EAI045 as a fourth-generation EGFR inhibitor.

Keywords: EGFR     tyrosine kinase inhibitor     AZD9291     EAI045    

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 83-93 doi: 10.1007/s11684-019-0682-z

Abstract: Recently, treatments using cetuximab, also named C225, an anti-EGFR monoclonal antibody, for CRC havebeen demonstrated to cause an S492R mutation in EGFR.However, little is known about the biological function of S492R EGFR.Our study indicated that EGFR and S492R EGFR accelerate the growth of CRC cells in vitro and <, can bind efficiently to S492R EGFR.

Keywords: S492R EGFR ectodomain mutation     colorectal cancer     mAb CH12     immunnotherapy    

Ultraviolet-B induced expression of hypoxia-inducible factor 1α, transferrin receptor through EGFR/PI3K

LI Yanhua, BI Zhigang

Frontiers of Medicine 2007, Volume 1, Issue 1,   Pages 79-86 doi: 10.1007/s11684-007-0016-4

Abstract: Expressions of epidermal growth factor receptor (EGFR), phosphor-EGF-R and TfR after UVB irradiationUVB induced activation of EGFR in HaCat cells and EGFR regulated expression of TfR and HIF-1α.EGFR (-/-) MEF did not increase the HIF1 expression following UVB irradiation (>0.05).In contrast, EGFR (+/+) MEF strongly enhanced HIF1α expression after UVB irradiation (<0.05).We conclude that UVB induces TfR and HIF-1αexpressions via EGFR/PI3K/AKT/DEC1 signaling pathway.

CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer

Frontiers of Medicine 2023, Volume 17, Issue 1,   Pages 105-118 doi: 10.1007/s11684-022-0934-1

Abstract: The third-generation epidermal growth factor receptor (EGFR) inhibitor osimertinib (OSI) has been approvedas the first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC).induced higher CD47 expression, an important anti-phagocytic immune checkpoint, via the NF-κB pathway in EGFR-mutantexploration of combining anti-CD47 antibody with OSI as a new strategy to enhance the anticancer efficacy in EGFR-mutant

Keywords: osimertinib     anti-CD47 antibody     combination strategy     ADCP     EGFR    

Title Author Date Type Operation

Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors

Journal Article

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors

Shuhang Wang,Yongping Song,Feifei Yan,Delong Liu

Journal Article

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang

Journal Article

Ultraviolet-B induced expression of hypoxia-inducible factor 1α, transferrin receptor through EGFR/PI3K

LI Yanhua, BI Zhigang

Journal Article

CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer

Journal Article